Efficacy and safety of fecal microbiota transplantation in the management of parkinson’s disease: a systematic review
Yehia Nabil, Mohamed Mohsen Helal, Israa Ahmed Qutob, Ali I. Abbas Dawoud, Salma Allam, Roaa Haddad, Ghaida Majid Manasrah, Esraa M. AlEdani, Wadi Sleibi, Ayhan faris, Amr K. Hassan, Varsha Nandwana
Abstract
BACKGROUND: Parkinson's disease (PD) involves progressive neurodegeneration with motor and non-motor symptoms. Gut microbiota alterations are implicated in PD pathogenesis, leading to interest in fecal microbiota transplantation (FMT) as a therapeutic option. This systematic review assesses the efficacy and safety of FMT in managing PD symptoms. METHODS: We conducted a comprehensive search across PubMed, Scopus, Web of Science, and Cochrane Central Controlled trials databases. Studies were screened based on predetermined inclusion criteria, focusing on randomized controlled trials (RCTs) involving FMT in PD patients. Two reviewers independently performed the data extraction and quality assessment. Key outcomes included improvements in motor and non-motor symptoms, quality of life, and adverse effects. RESULTS: Five RCTs involving 157 patients met the inclusion criteria. Some studies reported improvements in motor and non-motor symptoms, particularly with colonic FMT, while others found no significant benefit. One trial observed motor function worsening. FMT was generally well-tolerated, with mild and transient gastrointestinal side effects. CONCLUSION: FMT may relieve PD symptoms, but findings are inconsistent. Larger trials with standardized protocols are needed to determine its long-term efficacy and safety.